Johnson & Johnson (JNJ) Offering Possible 24.38% Return Over the Next 21 Calendar Days

Johnson & Johnson's most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $131.00 short call and a strike $136.00 long call offers a potential 24.38% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $131.00 by expiration. The full premium credit of $0.98 would be kept by the premium seller. The risk of $4.02 would be incurred if the stock rose above the $136.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.

The RSI indicator is below 20 which suggests that the stock is in oversold territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Johnson & Johnson

Is Johnson & Johnson Stock Losing Its Shine?
Wed, 24 Jul 2019 13:51:29 +0000
It's been a week since Johnson & Johnson (NYSE:JNJ) announced its Q2 results. While they beat expectations, JNJ stock has lost ground, as JNJ stock price fell 3.2% in the five trading days since it unveiled its earnings.Source: Shutterstock InvestorPlace – Stock Market News, Stock Advice & Trading TipsLooking through its earnings report, there's a lot to like about its business, but there are also several question marks that should make investors hesitant to own JNJ at this point. * 7 Stocks to Sell This Summer Earnings Season JNJ Has Failed to Deliver for Several YearsCEO Alex Gorsky proudly announced a 5.6% quarterly dividend increase on Apr. 25. JNJ stock now pays a $3.80 annual dividend that yields a respectable 2.9%. Gorsky went on to boast about the fact that the company's increased its annual dividend for 57 consecutive years, making it one of the more impressive Dividend Aristocrats trading on U.S. markets. While that's true, consider that over the past five years, the annualized total return of JNJ stock is just 7.2% with approximately 2.7% of that from dividends and 2% from buybacks of JNJ stock. Only 2.5% of its annualized return was from capital appreciation. Meanwhile, the Morningstar U.S. Total Market Index's total return was 10.5% over the same period, 3.32 percentage points higher than the return of JNJ stock. JNJ might have increased its dividend for 57 consecutive years, but many investors weren't around for a lot of those years. They want results today.Up 1.2% in 2019, JNJ stock is spinning its wheels. A Couple of LawsuitsOf the two significant lawsuits facing JNJ at the moment, the talcum powder issue is likely the bigger one, as it relates to the company's reputation. Johnson & Johnson's trustworthiness as a brand is on the line. If Alex Gorsky's crack legal team doesn't bring the company a big win, you can bet its sales will suffer in the future.At the moment, in addition to the 14,000 lawsuits from consumers alleging that its talc products caused ovarian cancer, the U.S. Justice Department and the SEC are investigating how much the company knew or didn't know about asbestos in its talc products. JNJ is on record disputing any link between its powder and cancer, despite the fact that, over the past three years, juries have awarded more than $5 billion to plaintiffs who have blamed the company for their ovarian cancer or for their loved ones' death from the disease. Bloomberg Intelligence estimates the final costs of civil suits against JNJ could be as high as $15 billion. Also, investors have filed lawsuits against the company alleging that JNJ failed to disclose its knowledge of the asbestos in its talc products to maintain its good name with consumers. Lastly, on July 15, the trial between the State of Oklahoma and Johnson & Johnson over the state's opioid crisis came to an end. The judge is expected to make a ruling in a month. The company says it's done everything by the book, while the state's argued that the company knew opioids were addictive, yet continued to oversupply the marketplace. I have no idea what the ruling will be, but two other drug companies have settled similar lawsuits for a total of $355 million. The state of Oklahoma believes its abatement plan to deal with the opioid crisis will cost it $17.5 billion over the next 30 years. Why would investors looking for yield pick JNJ stock when others are delivering similar returns with much less legal baggage? The Bottom Line on JNJ Stock Earlier this year I alleged that JNJ CEO Alex Gorsky is overpaid compared to other chief executives. My colleague, James Brumley, had previously advised investors to hold ten stocks forever. JNJ was one of them. I concluded that Gorsky and AT&T (NYSE:T) CEO Randall Stephenson were the two highest-paid of the ten CEOs with Gorsky delivering mediocre stock performance over the past three years while Stephenson's record was even worse.JNJ might have healthy financials, but I can't imagine why anyone interested in a safe investment would get into bed with a company that's got such a black cloud hanging over it. I can think of plenty of Dividend Aristocrats to buy for the long haul. JNJ stock isn't one of them. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 5G Stocks to Connect Your Portfolio To * 7 Stocks to Sell This Summer Earnings Season * 6 Upcoming IPOs for July The post Is Johnson & Johnson Stock Losing Its Shine? appeared first on InvestorPlace.

How to Invest in Cancer-Fighting Stocks
Tue, 23 Jul 2019 20:00:00 +0000
Seven steps to help you invest more effectively in the war on cancer.

Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View
Tue, 23 Jul 2019 14:16:02 +0000
Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.

Will Humira & Other Drugs Drive AbbVie's (ABBV) Q2 Earnings?
Tue, 23 Jul 2019 12:13:12 +0000
Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.

3 of the Most Rock-Solid Dividend Stocks in the World
Tue, 23 Jul 2019 10:06:00 +0000
These income stocks look incredibly secure for a long time to come.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.